Freiburg, Germany
Dermagnostix is a pioneering company established in 2021, focusing on advancing diagnostics in the field of dermatology. The company's slogan, "moving diagnostic frontiers in dermatology," underscores its commitment to revolutionizing clinical practice and enhancing patient outcomes through innovative solutions. Acknowledging that one-third of the global population suffers from skin conditions, Dermagnostix aims to address this pressing healthcare challenge, where existing diagnostics have not matched the advancements in treatments.
Their flagship product, PsorX, is the first molecular test designed for the differential diagnosis of psoriasis and eczema, promising to fill critical gaps in dermatological diagnostics. This system offers a streamlined process with its automated portable laboratory, providing rapid and reliable results.
Supported by a $2.50M grant from the European Innovation Council in March 2022, Dermagnostix is poised to capitalize on the growing demand for precision-focused dermatological solutions, presenting strong investment potential in a burgeoning industry.
